The stock of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has been Upgraded to Outperform from Mkt Perform by Bernstein in its latest research note that was published on September 10. Stifel analysts again handed out a Hold rating to IONS stock but they lifted target price for the shares in a flash note to investors on August 08. The price target has been raised from $48 to $47. Analysts at Stifel are sticking to their Hold recommendation. However, on August 07, they lifted target price for these shares to $48 from $55.Analysts at Stifel, made their first call for the stock with a Hold rating, according to a research note that dated back to August 07.
Ionis Pharmaceuticals, Inc., which has current market capitalization of above $10 Billion, published its last quarter earnings on June 30, 2019.
IONS surged by $2.19 during the normal trading session on Thursday and reaching a high of $67.02 during the day while it closed the day at $66.88. The Ionis stock had a high trading volume of 1.45 million shares on that day, which is high compared to the average daily volume of 1.05M shares. IONS has also gained 6.56% of its value over the past 7 days. However, the stock has surged by 4.70% in the 3 months of the year. Over the past six months meanwhile, it has lost 13.64% while it has added 23.71% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -8.5% from its 3 months high price. However, taking another look at IONS will indicate that it is trading +12.33% away from its 90-day low. Looking at the bigger picture, the Ionis Pharmaceuticals, Inc. stock has dropped by -22.76% from its 52-week high while it has surged by +54.56% from its 52-week low price.
On August 21, 2019 CROOKE STANLEY T, Chairman and CEO sold 22000 shares of the company. The average price for that transaction was $71.52 per share, which meant that CROOKE STANLEY T earned $1573440 selling the stocks. The sale was made public, with the document of the transaction filed with the SEC. Another insider trading occurred, with Chairman & CEO, CROOKE STANLEY T selling 10000 shares of this stock on July 18, 2019. The average selling price for the stock was $70.25 per share, with the sold stock accruing $702500. Following this transaction, the Chairman & CEO CROOKE STANLEY T now holds 7532 shares of the company, which is worth around $488299.6.
Ionis has around 273 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $241 Billion. The Ionis stock is bringing in revenue of over 12 months, which is roughly 162 Billion. Despite all that, Ionis Pharmaceuticals, Inc. is seeing things progressing very much as their y-o-y quarterly revenue surged by 37.96%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 54.17%. This figure is worse than the company’s 20-day Raw Stochastic average which currently stands at 54.17%. Over the past 20 days, Ionis’s Stochastic %K stood at 39.07% while its Stochastic %D was revealed to be 23.85%.